Answers are grounded in this paper and cite their sources.
Observational analysis assesses treatment timing impact in acute myeloid leukemia, suggesting biology-informed decisions improve patient outcomes.
TDT should be viewed as a biology-adapted decision rather than an urgency metric: short, purposeful delays to complete genomic profiling can optimize treatment selection without harming outcomes, whereas system-driven delays remain detrimental and inequitable.
No takes yet. Share an insight, caveat, or question.
Molica et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: